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Purpose/Objective: The Young Boost trial, a multicenter 
randomized controlled trial (NCT00212121), investigates 
whether a high boost dose leads to a lower recurrence rate in 
young patients treated with breast conserving therapy, with 
cosmetic outcome as the secondary objective. Here, we 
report the first results on 4 years cosmetic outcome and on 
factors influencing cosmetic outcome. 
Materials and Methods: From 2004-2011, 2421 breast cancer 
patients ≤ 50 yrs were included in The Netherlands, France 
and Germany. All patients were treated with breast 
conserving surgery, followed by whole breast irradiation. 
Patients were randomized to receive a standard low boost 
(n=1211) or a high boost (n=1210) to the tumor bed. The 
boost was delivered either sequentially or simultaneously 
(SIB), to an EQD2 of 50 Gy for the whole breast, 16 Gy for the 
low boost and 26 Gy for the high boost, respectively. 
Cosmetic outcome was scored prior to radiation therapy 
(baseline; BLN), at 1 year and at 4 years follow up (FU) 
according to the following three scoring systems: 
1. BCCT.core: Digital photographs were analyzed using a 
software program to extract an overall cosmetic score: 
excellent, good, fair or poor 
2. Physicians’ opinion: excellent, good, fair or poor 
3. Patients’ satisfactory score using a validated patient’s 
questionnaire: very satisfied, satisfied, not dissatisfied, 
dissatisfied or very dissatisfied 
The scores very satisfied or satisfied and good or excellent 
were grouped as ‘satisfactory’. Score percentages between 
the high and low boost group were compared with an exact 
or χ2.test. For analysis of potential risk factors (tumor 
location, irradiated boost volume, SIB versus sequential 
boost, chemotherapy (yes/no), postoperative complications 
(hematoma/infection/seroma) and seroma separately), the 
change from BLN to 4 yr FU was calculated and compared 
using Wilcoxon or Kruskal-Wallis rank sum tests for 
BCCT.core, assuming this was the most objective scoring 
system.  
Results: Patient characteristics including cosmetic scores 
were similar at BLN for both treatment arms. At 4 yrs, 
cosmetic outcome was significantly better in the low boost 
group than in the high boost group for all three cosmetic 
scores (fig 1): BCCT.core: 67% satisfactory in the low boost 
versus 55% in the high boost group (p=0.0009); physicians: 
63% in the low boost versus 48% in the high boost group 
(p<0.0001); and patients: 62% in the low boost versus 52% in 
the high boost group (p=0.0037).  
Significant risk factors for decline in BCCT.core score from 
BLN were high boost dose (p=0.0008), boost volume > 130 cc 
(p=0.041), chemotherapy (p=0.029) and seroma (p=0.034). 
Tumor location (p=0.39) and SIB versus sequential boost 
(p=0.68) were not significant. 
 
 
Conclusions: These first 4 year results of the Young Boost 
trial show that a high boost results in a worse cosmetic 
outcome. Other risk factors for worse cosmetic outcome are 
boost volume, chemotherapy and seroma.  
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Purpose/Objective: The aim of this prospective study was to 
develop a multivariable prediction model for the risk of 
severe fibrosis in the boost area after breast conserving 
surgery followed by radiotherapy with a simultaneous 
integrated boost (SIB) technique, with a follow-up of 5 years.  
Materials and Methods: The study population was composed 
of 1,030 disease-free patients treated for breast cancer 
(stage 0-III) after breast-conserving surgery, from 2005 to 
2008. The prescribed dose was 50.4 Gy on the whole breast 
with a boost up to 64.4 Gy or 67.2 Gy in 28 fractions. The 
primary endpoint was fibrosis grade II-III in the boost area, 
which was prospectively scored by the physician according to 
the CTCAE criteria v3.0. Univariate and multivariate analyses 
with a bootstrapping method were performed. 
Results: For 546 patients, complete follow-up and dosimetric 
data was available up to five years after treatment. Fibrosis 
grade II-III in the boost area was observed in 13.4% of cases. 
The multivariable analysis resulted in a prediction model with 
three independent variables, including patient age (years), 
percentage of breast volume receiving more than 55 Gy (V55, 
%) and the maximum radiation dose (Dmax, Gy) in the breast. 
The model performed reasonably with regard to 
discrimination (Area under the Curve: 0.66, 95%-CI: 0.59-
0.73) and calibration (Hosmer and Lemeshow test sig. 0.42). 
In this model, the probability of fibrosis in the breast 
increases with increase of Dmax, V55 and age, as shown in 
figure 1. 
